The proportion of patients with 12-week composite confirmed disability progression was 33 and 40%, respectively, with ocrelizumab and placebo. HealthDay News — For patients with primary progressive ...
PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...
A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows ...
Ocrelizumab (Ocrevus) delayed overall disability progression and worsening of upper limb function in people with primary progressive multiple sclerosis (PPMS) over 144 weeks, the ORATORIO-HAND (O'HAND ...
Iron dysregulation contributes to MS progression through oxidative stress, ferroptosis, and immune activation, affecting neuronal and immune cell function. Both iron overload and deficiency exacerbate ...
Findings showed treatment with tolebrutinib did not significantly delay disability progression compared with placebo. A phase 3 study evaluating tolebrutinib for the treatment of primary progressive ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results